Top stories in endocrinology: FDA warns of cancer risk with obesity drug, Lilly to offer half-price generic insulin
Click Here to Manage Email Alerts
The FDA issued a safety alert for the weight-loss drug lorcaserin after results from a clinical trial showed it caused a possible increase in cancer risk. It was the week’s top story in endocrinology.
Another top story was about the pharmaceutical company Lilly, which will start offering “authorized generic” versions of two of its insulins with list prices 50% lower than the branded version, starting in April.
FDA warns of possible cancer risk with obesity drug
The FDA issued a safety alert for the serotonin receptor agonist lorcaserin, warning that results from a clinical trial assessing safety show a possible increased risk for cancer with the weight-management medicine, according to an agency press release. Read more.
Lilly to offer half-price, ‘authorized generic’ insulins
Lilly announced that it will offer “authorized generic” versions of two of its most popular insulins beginning in April, with list prices 50% lower than the company’s branded versions, according to an industry press release. Read more.
FDA approves CV risk indication for semaglutide
The FDA approved a new indication for the GLP-1 receptor agonist semaglutide to reduce the risk for major adverse cardiovascular events in adults with type 2 diabetes with known cardiovascular disease, according to a press release from Novo Nordisk. Read more.
‘Metabolic flexibility’ reduced during pregnancy for women with overweight or obesity
Lipid oxidation rate — an indicator of “metabolic flexibility” — may be greater among women with normal weight vs. women with overweight or obesity during pregnancy, according to findings published in Metabolism. In addition, insulin resistance and inflammation may be influenced by this flexibility. Read more.
Mobile closed-loop insulin system bests sensor-augmented pump in preventing hypoglycemia
Patients with type 1 diabetes may be able to avoid hypoglycemia more effectively without an increase in hyperglycemic episodes if they use a mobile closed-loop control system instead of a sensor-augmented pump, according to findings published in Diabetes Care. Read more.